AMGN Quote, Financials, Valuation and Earnings

Johnson & Johnson has a net margin of 6.9% compared to Amgen's net margin of 15.24%. Amgen's return on equity of 66.87% beat Johnson & Johnson's return on equity of 19.98%.

Amgen has a consensus price target of $315.95, signalling upside risk potential of 0.71%. On the other hand Johnson & Johnson has an analysts' consensus of $169.07 which suggests that it could grow by 3.84%. Given that Johnson & Johnson has higher upside potential than Amgen, analysts believe Johnson & Johnson is more attractive than Amgen.

Amgen has a beta of 0.527, which suggesting that the stock is 47.288% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.473, suggesting its less volatile than the S&P 500 by 52.686%.

Amgen has a quarterly dividend of $2.38 per share corresponding to a yield of 2.91%. Johnson & Johnson offers a yield of 3.05% to investors and pays a quarterly dividend of $1.24 per share. Amgen pays 118.14% of its earnings as a dividend. Johnson & Johnson pays out 84.05% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Amgen's is not.

Amgen quarterly revenues are $9.1B, which are smaller than Johnson & Johnson quarterly revenues of $22.5B. Amgen's net income of $627M is lower than Johnson & Johnson's net income of $3.4B. Notably, Amgen's price-to-earnings ratio is 41.55x while Johnson & Johnson's PE ratio is 28.12x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amgen is 5.07x versus 4.45x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly and has a net margin of 6.9% compared to Amgen's net margin of 32.59%. Amgen's return on equity of 66.87% beat Eli Lilly and's return on equity of 80.24%.

Amgen has a consensus price target of $315.95, signalling upside risk potential of 0.71%. On the other hand Eli Lilly and has an analysts' consensus of $1,006.63 which suggests that it could grow by 23.74%. Given that Eli Lilly and has higher upside potential than Amgen, analysts believe Eli Lilly and is more attractive than Amgen.

Amgen has a beta of 0.527, which suggesting that the stock is 47.288% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.817%.

Amgen has a quarterly dividend of $2.38 per share corresponding to a yield of 2.91%. Eli Lilly and offers a yield of 0.66% to investors and pays a quarterly dividend of $1.50 per share. Amgen pays 118.14% of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Amgen's is not.

Amgen quarterly revenues are $9.1B, which are smaller than Eli Lilly and quarterly revenues of $13.5B. Amgen's net income of $627M is lower than Eli Lilly and's net income of $4.4B. Notably, Amgen's price-to-earnings ratio is 41.55x while Eli Lilly and's PE ratio is 69.47x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amgen is 5.07x versus 16.33x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of 6.9% compared to Amgen's net margin of 24.22%. Amgen's return on equity of 66.87% beat Regeneron Pharmaceuticals's return on equity of 15.78%.

Amgen has a consensus price target of $315.95, signalling upside risk potential of 0.71%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $923.05 which suggests that it could grow by 38.42%. Given that Regeneron Pharmaceuticals has higher upside potential than Amgen, analysts believe Regeneron Pharmaceuticals is more attractive than Amgen.

Amgen has a beta of 0.527, which suggesting that the stock is 47.288% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.270, suggesting its less volatile than the S&P 500 by 72.991%.

Amgen has a quarterly dividend of $2.38 per share corresponding to a yield of 2.91%. Regeneron Pharmaceuticals offers a yield of 0.13% to investors and pays a quarterly dividend of $0.88 per share. Amgen pays 118.14% of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend.

Amgen quarterly revenues are $9.1B, which are larger than Regeneron Pharmaceuticals quarterly revenues of $3.8B. Amgen's net income of $627M is lower than Regeneron Pharmaceuticals's net income of $917.7M. Notably, Amgen's price-to-earnings ratio is 41.55x while Regeneron Pharmaceuticals's PE ratio is 17.42x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amgen is 5.07x versus 5.40x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Viking Therapeutics has a net margin of 6.9% compared to Amgen's net margin of --. Amgen's return on equity of 66.87% beat Viking Therapeutics's return on equity of --.

Amgen has a consensus price target of $315.95, signalling upside risk potential of 0.71%. On the other hand Viking Therapeutics has an analysts' consensus of $99.29 which suggests that it could grow by 221.44%. Given that Viking Therapeutics has higher upside potential than Amgen, analysts believe Viking Therapeutics is more attractive than Amgen.

Amgen has a beta of 0.527, which suggesting that the stock is 47.288% less volatile than S&P 500. In comparison Viking Therapeutics has a beta of 0.903, suggesting its less volatile than the S&P 500 by 9.651%.

Amgen has a quarterly dividend of $2.38 per share corresponding to a yield of 2.91%. Viking Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amgen pays 118.14% of its earnings as a dividend. Viking Therapeutics pays out -- of its earnings as a dividend.

Amgen quarterly revenues are $9.1B, which are larger than Viking Therapeutics quarterly revenues of --. Amgen's net income of $627M is higher than Viking Therapeutics's net income of -$35.4M. Notably, Amgen's price-to-earnings ratio is 41.55x while Viking Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amgen is 5.07x versus -- for Viking Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.